Abstract
Background
In Japan, National Health Insurance (NHI) has ensured that all Japanese citizens can use the health services they need for more than 50 years. This paper gives an overview of the Japanese NHI drug price listing scheme and practice, and it also discusses the issue of drug price setting and health insurance system from the viewpoint of better patient access to new drugs as well as the environment for innovative new drug development.
Methods
For each New Molecular Entity (NME) approved between October 2004 and December 2014, we checked its presence in the list of NHI drug prices as of January 31, 2015, to calculate the NHI coverage rate and the average time between marketing approval and the date of NHI listing.
Results
A total of 304 NMEs were listed in the NHI price list during the study period, and the NHI coverage rate (excepting preventive vaccines) was 97.4%. The average time between marketing authorization and the initiation of reimbursement was 66 days. There were 88 drugs that gained premiums for innovativeness/usefulness.
Conclusions
From the view of NHI coverage scope and speed, the hurdle to access new drugs in Japan is shown to be lower than in other countries that also set public prices for reimbursement. Although the difficulty of controlling health expenditures increases, drug pricing that properly reflects the drug’s clinical value is important in that it also furthers the development of medical technology. Better price setting can also facilitate patient access to innovative drugs.
Similar content being viewed by others
References
Centre for Innovation in Regulatory Science. New drug approvals in ICH countries, 2005–2014: Focus on facilitated regulatory pathways and orphan designations. R&D Briefing 57. April 2015. http://www.cirsci.org/sites/default/files/CIRS_R&D_57_ICH_%20approval_%20times_2005-2014_%2006072015.pdf. Accessed October 20, 2015.
World Health Organization (WHO). The world health report. Health systems financing: the path to universal coverage. http://www.who.int/whr/2010/10_summary_en.pdf?ua=1. Accessed October 20, 2015.
European Federation of Pharmaceutical Industries and Associations (EFPIA). Patients’ W.A.I.T. indicator—Report 2011. http://www.efpia.eu/documents/33/64/Market-Access-Delays. Accessed October 20, 2015.
Cohen J., Faden L., Predaris S., Young B. Patient access to pharmaceuticals: an international comparison. Eur J Health Econ. 2007;8:253–266.
Cohen J., Cairns C., Paquette C., Faden L. Comparing patient access to pharmaceuticals in the UK and in the US. Appl Health Econ Health Policy. 2006;5:177–187.
Japanese Ministry of Health, Labour and Welfare (MHLW). Annual health, labour and welfare report, 2012–2013. http://www.mhlw.go.jp/english/wp/wp-hw7/index.html. Accessed October 20, 2015.
Japanese Ministry of Health, Labour and Welfare (MHLW). About rule of NHI price calculation method in FY 2014 [in Japanese]. http://www.mhlw.go.jp/file/06-Seisakujouhou-12400000-Hokenkyoku/0000039400.pdf. Accessed October 20, 2015.
IMS consulting group. Pricing & market access outlook, 2012. http://www.imshealth.com/deployedfiles/consulting/Global/Content/Our%20Latest%20Thinking/Static%20Files/IMS%20Outlook%2020-09-2012.pdf. Accessed October 20, 2015.
European Commission. Proposal for a directive of the European parliament and of the council relating to the transparency of measures regulating the price of medicinal products for human use and their inclusion in the scope of public health insurance systems. http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52012AE1573&from=EN. Accessed October 20, 2015.
Centers for Medicare and Medicaid Services (CMS). Medicare Modernization Act final guidelines—formularies: CMS strategy for affordable access to comprehensive drug coverage guidelines for reviewing prescription drug plan formularies and procedures. https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/downloads/FormularyGuidance.pdf. Accessed October 20, 2015.
Pretium. Drug tracker report: July 2010. 2010. http://www.pretium.com.au/drugtrackerPDF/Drug%20Tracker%20-%2010%2007.pdf. Accessed October 20, 2015.
Pearce A, van Gool K, Haywood P, Haas M. Delays in access to affordable medicines: putting policy into perspective. Aust Health Rev. 2012;3:412–418.
Mark R, Brett S. Access delayed, access denied 2012: waiting for new medicines in Canada. Fraser Institute. http://www.fraserinstitute.org/sites/default/files/access-delayed-access-denied-2012.pdf. Accessed October 20, 2015.
Tsuji K, Tsutani K. Approval of new drugs 1999–2007: comparison of the US, the EU and Japan situations. J Clin Pharm Ther. 2010;35:289–301.
Ueno T, Asahina Y, Tanaka A, Yamada H, Nakamura M, Uyama Y. Significant differences in drug lag in clinical development among various strategies used for regulatory submissions in Japan. Clin Pharmacol Ther. 2014;95:533–541.
Japanese Ministry of Health, Labour and Welfare (MHLW). Basic principles on global clinical trials 2007. http://www.pmda.go.jp/files/000153265.pdf. Accessed October 20, 2015.
Japanese Ministry of Health, Labour and Welfare (MHLW). New 5 yearly clinical trial activation plan 2007 [in Japanese]. http://www.mhlw.go.jp/shingi/2007/03/dl/s0330-5a.pdf. Accessed October 20, 2015.
Japanese Ministry of Health, Labour and Welfare (MHLW). Basic principles on global clinical trials (reference cases) 2012. http://www.pmda.go.jp/files/000157451.pdf. Accessed October 20, 2015.
Japanese Pharmaceuticals and Medical Devices Agency (PMDA). PMDA current situation and aim for the future. https://www.pmda.go.jp/files/000164202.pdf. Accessed October 20, 2015.
Hashimoto H., Ikegami N., Shibuya K., Izumida N., Noguchi H., Yasunaga H., et al. Cost containment and quality of care in Japan: is there a trade-off? Lancet. 2011;378:1174–1182.
Shibuya K., Hashimoto H., Ikegami N., Nishi A., Tanimoto T., Miyata H., et al. Future of Japan’s system of good health at low cost with equity: beyond universal coverage. Lancet. 2011;378:1256–1273.
Organisation for Economic Co-operation and Development (OECD). Health at a Glance 2013. http://www.oecd.org/els/health-systems/Health-at-a-Glance-2013.pdf. Accessed October 20, 2015.
Aetna. The fact about rising health care costs. Underlying medical costs drive growth 2012. http://www.aetna.com/news/2012/CostDrivers.pdf. Accessed October 20, 2015.
Japanese Central Social Insurance Medical Council. Subcommittee of Chuikyo to discuss cost-effectiveness assessment. Interim report to propose a scheme of cost-effectiveness assessment [in Japanese]. http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000095706.pdf. Accessed October 20, 2015.
Japanese Ministry of Health, Labour and Welfare (MHLW). Vision of pharmaceutical industry 2013 [in Japanese]. http://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iryou/shinkou/dl/vision_2013a.pdf. Accessed October 20, 2015.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Takayama, A., Narukawa, M. Pharmaceutical Pricing and Reimbursement in Japan: For Faster, More Complete Access to New Drugs. Ther Innov Regul Sci 50, 361–367 (2016). https://doi.org/10.1177/2168479015619202
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479015619202